Protocol Ledger

NCT06452277 · Phase III · RECRUITING

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Grow

Interventional Phase III clinical trial protocol NCT06452277 sponsored by Bayer in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-08-28 Enrollment: 444 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06452277
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)444 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06452277
Protocol FieldVerified Registry Value
NCT IdentifierNCT06452277
Consolidated Lead SponsorBayer
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment444 participants (ESTIMATED)
Registered Start Date2024-08-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI